For research and educational purposes only. Not medical advice.
Empagliflozin Reference
Educational, not medical advice reference for Empagliflozin: Metabolic; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
EMPA-REG OUTCOME (Zinman 2015 NEJM, n=7,020 adults with T2D and established CVD) reported a 14 percent relative reduction in the primary 3-component MACE composite and a 32 percent relative reduction in cardiovascular death over a median 3.1 years - the first SGLT2 trial to show a mortality benefit. EMPEROR-Reduced and EMPEROR-Preserved subsequently established heart-failure benefit across the ejection fraction spectrum; EMPA-KIDNEY established CKD benefit.
Regulatory and posture
- Categories
- Metabolic
- Aliases
- Jardiance, SGLT2 inhibitor (small molecule, not a peptide)
- Evidence posture
- human
- Regulatory status
- FDA-approved as Jardiance for type 2 diabetes (2014), reduction in cardiovascular death in adults with T2D and established cardiovascular disease (2016), heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023). Fixed-dose combinations with metformin (Synjardy) and linagliptin (Glyxambi) are also approved.
- Content review status
- label verified